Cymabay Therapeutics Inc Stock
Price
Target price
-
-
-
-
-
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Cymabay Therapeutics Inc Stock
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Cymabay Therapeutics Inc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Cymabay Therapeutics Inc in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cymabay Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cymabay Therapeutics Inc | - | - | - | - | - | - | - |
| Heron Therapeutics Inc. | 7.600% | -50.806% | -66.818% | -80.098% | -67.145% | -65.143% | -96.715% |
| Evolus Inc | -2.000% | 2.559% | 6.592% | -31.006% | 4.440% | -29.292% | -36.402% |
| Rhythm Pharmaceuticals | -1.330% | -1.316% | -8.537% | 31.579% | -19.786% | 374.684% | 393.421% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-11
Assessing the financial standing of CymaBay, a frontrunner in the Biotechnology & Medical Research industry, the company portrays a mixed bag of circumstances. In one vein, its financial posture wrestles with certain impediments, while, on the other hand, it arms itself with potential growth drivers.
Analysis of financial ratios and its balance sheet unfolds a few favorable facets.
On the flip side, a host of challenges warrants immediate attention.
Comments
News
Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline
Gilead Sciences (NASDAQ:GILD) Chief Commercial Officer and Head of Corporate Affairs Johanna Mercier said the company is leaning on its HIV business
